Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML

Video

In Partnership With:

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

In terms of the subsets evaluated in a phase III study presented at the 2017 ASCO Annual Meeting, results also showed that CPX-351 had a benefit in patients with treatment-related AML, Erba explains. In other subset analyses, there have been benefits observed with CPX-351 in patients over the age of 70, as well as in patients who went to receive allogeneic stem cell transplant.

In fact, the survival of patients who were treated on the randomized phase III study who went on to receive transplant was superior if they received CPX-351 versus 7+3. Therefore, CPX-351 is a major breakthrough in the treatment of these high-risk patients, he adds. Going forward, researchers will explore what other patient populations this therapy is effective in and what other combinations they may need to consider.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD